Literature DB >> 15311150

Validation of the A&D UA-774 (UA-767Plus) device for self-measurement of blood pressure.

Paolo Verdecchia1, Fabio Angeli, Fabrizio Poeta, Gian Paolo Reboldi, Claudia Borgioni, Loretta Pittavini, Carlo Porcellati.   

Abstract

OBJECTIVES: To determine the accuracy of the UA-774 (UA-767Plus) blood pressure monitor developed by the A&D Company.
METHODS: Device evaluation was performed according to the modified British Hypertension Society (BHS) protocol released in 1993. Eighty-five subjects with characteristics outlined in the BHS protocol were recruited among those attending the outpatient clinic of the Department of Cardiovascular Disease, Hospital 'R. Silvestrini', Perugia, Italy. The A&D blood pressure monitor was evaluated according to the various steps of the protocol. Sequential readings were taken for the main validation test. Outcome was classified according to the criteria of BSH recommendations, which are based on four areas of accuracy differing from the mercury standard by 5, 10 and 15 mmHg, or more.
RESULTS: The device achieved a grade A for systolic and a grade A for diastolic blood pressure. Mean blood pressure difference (+/-1 SD) between device and observers was -1.01+/-7.14 mmHg for systolic blood pressure and -1.42+/-7.61 mmHg for diastolic blood pressure. There was no systematic change in the device-observed difference over a wide range of blood pressure values
CONCLUSIONS: These data show that the A&D UA-774 (UA-767Plus) device satisfies the BSH recommendations for accuracy for systolic and diastolic blood pressure.

Entities:  

Mesh:

Year:  2004        PMID: 15311150     DOI: 10.1097/00126097-200408000-00008

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  7 in total

1.  Randomized clinical trial to assess the effectiveness of remote patient monitoring and physician care in reducing office blood pressure.

Authors:  Yoon-Nyun Kim; Dong Gu Shin; Sungha Park; Chang Hee Lee
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

2.  High Prevalence of Hypertension in a Danish Population Telemedical Home Measurement of Blood Pressure in Citizens Aged 55-64 Years in Holstebro County.

Authors:  Nikolai Hoffmann-Petersen; Torsten Lauritzen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Am J Hypertens       Date:  2015-07-23       Impact factor: 2.689

3.  Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness.

Authors:  José Luis Macarlupú; Gustavo Vizcardo-Galindo; Rómulo Figueroa-Mujíca; Nicolas Voituron; Jean-Paul Richalet; Francisco C Villafuerte
Journal:  Exp Physiol       Date:  2021-09-30       Impact factor: 2.858

4.  Short-term telemedical home blood pressure monitoring does not improve blood pressure in uncomplicated hypertensive patients.

Authors:  N Hoffmann-Petersen; T Lauritzen; J N Bech; E B Pedersen
Journal:  J Hum Hypertens       Date:  2016-06-23       Impact factor: 3.012

5.  Orthostatic hypotension, diabetes, and falling in older patients: a cross-sectional study.

Authors:  Kornelis J J van Hateren; Nanne Kleefstra; Marco H Blanker; Lielith J Ubink-Veltmaat; Klaas H Groenier; Sebastiaan T Houweling; Adriaan M Kamper; Klaas van der Meer; Henk J G Bilo
Journal:  Br J Gen Pract       Date:  2012-10       Impact factor: 5.386

6.  Validation of four automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension.

Authors:  Jalil Belghazi; Ramzi N El Feghali; Thérèse Moussalem; Maya Rejdych; Roland G Asmar
Journal:  Vasc Health Risk Manag       Date:  2007

7.  Evaluation of an mHealth Medication Regimen Self-Management Program for African American and Hispanic Uncontrolled Hypertensives.

Authors:  Tatiana M Davidson; John McGillicuddy; Martina Mueller; Brenda Brunner-Jackson; April Favella; Ashley Anderson; Magaly Torres; Kenneth J Ruggiero; Frank A Treiber
Journal:  J Pers Med       Date:  2015-11-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.